Drugs that contain Atorvastatin Calcium
1. Atorvaliq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
| US11654106 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
Market Authorisation Date: 01 February, 2023
Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...
Dosage: SUSPENSION;ORAL
More Information on Dosage
ATORVALIQ family patents
2. Lipitor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5969156 | UPJOHN | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126971 | UPJOHN | Stable oral CI-981 formulation and process for preparing same |
Jan, 2013
(11 years ago) | |
|
US6126971 (Pediatric) | UPJOHN | Stable oral CI-981 formulation and process for preparing same |
Jul, 2013
(10 years ago) | |
| US5686104 | UPJOHN | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | UPJOHN | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
|
US5969156 (Pediatric) | UPJOHN | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-204) | Jun 23, 2020 |
Market Authorisation Date: 17 December, 1996
Treatment: Method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia
Dosage: TABLET;ORAL
How can I launch a generic of LIPITOR before it's drug patent expiration?
More Information on Dosage
LIPITOR family patents